All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Janani Reisenauer, MD
Disclosure(s): Emmi Solutions, LLC: Advisory Board (Terminated, February 4, 2023); Isola Therapeutics, Inc.: Consultant (Terminated, April 5, 2023); Manua Kea Technologies: Advisory Board (Terminated, February 8, 2023); Noah Medical: Consultant (Terminated, August 14, 2022)

David Cooke, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing); Bristol Myers Squibb: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Presentations

1. Single Stage Robotic Navigational Bronchoscopy and Lung Resection
   Saiesh R. Voppuru, MBBS
    
2. A Phase 2 Clinical Trial of VGT-309, a Quenched Activity-Based Probe for Intraoperative Molecular Imaging of Pulmonary Malignancies
   Patrick Bou-Samra, MD
    
3. Commentary: Intraoperative Molecular Imaging in Lung Surgery
   Sunil Singhal, MD
    
4. Transbronchial Microwave Ablation
   Kelvin K.W Lau, MA BM BCh (Ox) DPhil FRCS(CTh)
   Disclosure(s): , Medtronic: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Endowave: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Philips: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
    
5. Intratumoral Injection of Chemotherapy
   C. Matthew Kinsey, MD, MPH
   Disclosure(s): Galvanize Therapeutics Inc: Consultant (Ongoing); Johnson and Johnson: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Nanology: Consultant (Ongoing); Quantitative Image Solutions: Owner/Co-Owner Founder/Co-Founder (Ongoing)
    
6. The Application of an Artificial Intelligence Algorithm to Predict Lymph Node Malignancy in Non-Small Cell Lung Cancer
   Yogita S. Patel
    
7. Circulating tumor cells (CTCs); Predictor of postoperative recurrence risk and benefit of adjuvant therapy of NSCLC
   Noriyoshi Sawabata, MD, PhD
    
8. Commentary: Circulating Tumor Cells and ctDNA
   James Isbell, MD, MSCI
   Disclosure(s): Astra Zeneca: Advisory Board (Terminated, April 30, 2023); Merck & Co.: Advisory Board (Terminated, February 28, 2023)